Quince Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is developing a novel disease-modifying therapeutic to address the unmet medical need associated with pulmonary disorders. Its lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of pulmonary conditions associated with dysfunctional mammalian target of rapamycin activity. It is evaluating the use of LAM-001 as a treatment for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and for patients with bronchiolitis obliterans syndrome post lung transplant (BOS). It also completed a Phase 2a trial, which enrolled patients with pulmonary arterial hypertension as well as patients with PH-ILD and sarcoidosis associated pulmonary hypertension (SAPH) where it achieved clinically relevant improvement across multiple endpoints, including pulmonary vascular resistance and others. more
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| IRLA | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| IRLA | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
IRulya Therapeutics Inc (IRLA) share price today is $32.4
Yes, Indians can buy shares of IRulya Therapeutics Inc (IRLA) on Vested. To buy
Yes, you can purchase fractional shares of IRulya Therapeutics Inc (IRLA) via the Vested app. You can start investing in IRulya Therapeutics Inc (IRLA) with a minimum investment of $1.
You can invest in shares of IRulya Therapeutics Inc (IRLA) via Vested in three simple steps:
The 52-week high price of IRulya Therapeutics Inc (IRLA) is $. The 52-week low price of IRulya Therapeutics Inc (IRLA) is $.
The price-to-earnings (P/E) ratio of IRulya Therapeutics Inc (IRLA) is
The price-to-book (P/B) ratio of IRulya Therapeutics Inc (IRLA) is 0.00
The dividend yield of IRulya Therapeutics Inc (IRLA) is 0.00%
The market capitalization of IRulya Therapeutics Inc (IRLA) is
The stock symbol (or ticker) of IRulya Therapeutics Inc is IRLA
Consider the share price of IRulya Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether IRulya Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in IRulya Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the IRulya Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of IRulya Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that IRulya Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied
